Research ArticleHEALTH AND MEDICINE

Targeted delivery of antisense oligonucleotides to pancreatic β-cells

See allHide authors and affiliations

Science Advances  17 Oct 2018:
Vol. 4, no. 10, eaat3386
DOI: 10.1126/sciadv.aat3386

Article Information

vol. 4 no. 10

Online ISSN: 
History: 
  • Received for publication February 15, 2018
  • Accepted for publication September 12, 2018
  • .

Author Information

  1. C. Ämmälä1,*,
  2. W. J. Drury III1,
  3. L. Knerr1,
  4. I. Ahlstedt1,
  5. P. Stillemark-Billton1,
  6. C. Wennberg-Huldt1,
  7. E.-M. Andersson1,
  8. E. Valeur1,
  9. R. Jansson-Löfmark1,
  10. D. Janzén1,
  11. L. Sundström2,
  12. J. Meuller2,
  13. J. Claesson2,
  14. P. Andersson3,
  15. C. Johansson3,
  16. R. G. Lee4,
  17. T. P. Prakash4,
  18. P. P. Seth4,*,
  19. B. P. Monia4 and
  20. S. Andersson1
  1. 1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  2. 2Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  3. 3Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  4. 4Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
  1. *Corresponding author. Email: carina.ammala{at}astrazeneca.com (C.Ä.); pseth{at}ionisph.com (P.P.S.)

Altmetric

Article usage

Article usage: October 2018 to March 2021

AbstractFullPdf
Oct 2018042101259
Nov 201801100407
Dec 20180641179
Jan 20191531134
Feb 201921337109
Mar 20197337120
Apr 20198431101
May 20195403117
Jun 2019429486
Jul 20196355182
Aug 20192325110
Sep 2019025881
Oct 20193399154
Nov 20190253101
Dec 2019030189
Jan 20202347120
Feb 20200294114
Mar 2020229097
Apr 2020031294
May 20201281128
Jun 20200308143
Jul 2020030789
Aug 2020420981
Sep 20200269122
Oct 20200316114
Nov 20200326145
Dec 20202323133
Jan 20213339123
Feb 20211287136
Mar 202113921

Stay Connected to Science Advances

Navigate This Article